Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress
22 nov. 2024 04h49 HE
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...
PROTAC Targeted Protein Degraders Market Clinical Trials Insight to 2027 - Emerging PROTAC Therapeutics Set to Revolutionize Targeted Protein Degradation in Clinical Trials
23 oct. 2024 12h02 HE
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
22 août 2024 16h30 HE
|
Travere Therapeutics, Inc.
Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.
Anti TIGIT Antibodies Clinical Trials Market Outlook to 2028: Insight on 50+ Anti TIGIT Antibodies in Clinical Trials
09 août 2024 05h22 HE
|
Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT...
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
20 juin 2024 04h23 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In recent...
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
14 déc. 2023 07h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3...
United States Clinical Trial Data Management Service Market Insights Report 2023-2028 Featuring Prominent Vendors - IQVIA,SYNEOS, ICON and Labcorp
21 nov. 2023 04h38 HE
|
Research and Markets
Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The "US Clinical Trial Data Management Service Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering. The US...
Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights 2022
08 févr. 2023 13h23 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.This...
Global Hemophilia-A Clinical Trial Pipeline Report 2022
02 févr. 2023 13h38 HE
|
Research and Markets
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia A Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.The report Hemophilia A...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
02 juil. 2019 09h00 HE
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...